Report from SNM: Antibody-labeled radiotherapy overcomes leukemia treatment resistance
A monoclonal antibody-labeled radioimmunotherapy may help overcome a leukemia resistant to radio- and chemotherapy, according to a report presented at the Society of Nuclear Medicine meeting in San Diego.
A monoclonal antibody-labeled radioimmunotherapy may help overcome a leukemia resistant to radio- and chemotherapy, according to a report presented at the Society of Nuclear Medicine meeting in San Diego.
Molecular biologist Dr. Claudia Friesen of the University of Ulm presented results Sunday showing that alpha-emitter Bi-213-labeled anti-CD45 antibody breaks resistance to radiation therapy and chemotherapy in leukemia cells by overcoming DNA repair that plays an important role in that resistance.
Targeted alpha particle radioimmunotherapy increases the dose to leukemia cells by two orders of magnitude and causes apoptosis of single-targeted leukemia cells while sparing nontarget tissues from detrimental radiation effects, Friesen said. Therapeutic efficiency is increased, and nonspecific toxicity to normal organs and tissues is decreased.
Investigations at the University of Ulm suggest targeted alpha particle therapy is much more potent than targeted beta particle or external-beam radiation therapy. Low doses of alpha particles caused prompt and complete cell death through the induction of apoptosis in sensitive and resistant tumor cells.
"Our work considerably expands options for therapeutically applied radionuclides," Friesen said. "This technique will have a wide application in many solid tumors, using suitable peptides as carriers of alpha-emitting radionuclides."
Understanding the molecular mechanisms of sensitivity and the sources of resistance of tumor cells to radiation and chemotherapeutic drugs is considered crucial to developing novel treatment options in leukemia and solid tumor therapy. The Ulm group plans to focus on identifying novel molecular targets using gene expression technologies and high-throughput techniques for synthesis and selection of high-affinity peptides as carriers of radioisotopes both for diagnostic imaging and targeted internal radiotherapy.
Zevalin launches era of agents that combine imaging, therapy
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
